Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of BMS-298585 [muraglitazar] in combination with glyburide [glibenclamide] therapy in subjects with type 2 diabetes who have inadequate glycemic control on sulfonylurea therapy alone

Next Previous
X
Search
Trial Profile

A phase 3, randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of BMS-298585 [muraglitazar] in combination with glyburide [glibenclamide] therapy in subjects with type 2 diabetes who have inadequate glycemic control on sulfonylurea therapy alone

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Muraglitazar (Primary) ; Glibenclamide
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PPAR-COMBO
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 02 Nov 2006 Status change
    • 31 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top